Wolfe Research analyst Andy Chen downgraded Akero Therapeutics (AKRO) to Peer Perform from Outperform following Novo Nordisk’s (NVO) plan to acquire Akero for $4.7B upfront, equivalent to about $54 per share.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Akero Therapeutics rises 16.6%
- Midday Fly By: Delta beats, PepsiCo names new CFO
- Akero downgraded to Market Perform from Outperform at LifeSci Capital
- Cautious Hold Rating on Akero Therapeutics Amid Novo Nordisk Acquisition and Regulatory Uncertainties